Non-small cell lung cancer squamous · 9 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Gemcitabine (GCb) and Durvalumab N/A - protocol | — | R 269 756 | 28d | — | — | ~12 | ~R 2 132 630 indirect | — |
Cisplatin and Gemcitabine (GC) and Durvalumab Variant #02 | — | R 267 040 | 28d | — | ~12.9 mo | ~8 | ~R 1 346 116 PFS proxy · indirect | 3 |
Carboplatin and Paclitaxel (CP) and Durvalumab Variant #03 | — | R 232 682 | 28d | ~10.2 mo | — | ~6 | ~R 869 291 PFS proxy · indirect | 1 |
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01 | — | R 85 626 | 21d | — | — | 36 | R 2 992 297 PFS proxy | 1 |
Carboplatin and Gemcitabine (GCb) Variant #01 | — | R 4 414 | 21d | ~5.3 mo | ~12.9 mo | ~2 | ~R 8 829 PFS proxy · indirect | 7 |
Cisplatin and Gemcitabine (GC) Variant #01 | — | R 3 933 | 21d | — | — | 6 | R 23 595 PFS proxy | 2 |
Cisplatin and Gemcitabine (GC) and Nivolumab Variant #01 Partial | — | R 3 785 | 21d | — | — | 22 | R 22 713 PFS proxy | 1 |
Cisplatin and Docetaxel (DC) Variant #05 | — | R 3 185 | 21d | ~4.2 mo | ~11.4 mo | ~3 | ~R 9 556 PFS proxy · indirect | 2 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | ~4.9 mo | ~12.9 mo | ~18 | ~R 18 445 PFS proxy · indirect | 14 |
9 of 9 regimens shown